|
1.
|
|
10 p, 476.1 KB |
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
/
Le Tourneau, C. (Paris-Saclay University) ;
Becker, H. (University of Freiburg) ;
Claus, R. (Medical Faculty Augsburg University) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Ricci, F. (Paris-Saclay University) ;
Fritsch, R. (University of Freiburg) ;
Silber, Y. (Medical Faculty Augsburg University) ;
Hennequin, A. (Centre Georges-François Leclerc) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Jayadeva, G. (Boehringer Ingelheim International GmbH) ;
Luedtke, D. (Boehringer Ingelheim Pharma GmbH and Co KG) ;
He, M. (Boehringer Ingelheim Pharmaceuticals Inc.) ;
Isambert, N. (Centre Georges-François Leclerc) ;
Universitat Autònoma de Barcelona
BI 836880 is a humanized bispecific nanobody® that inhibits vascular endothelial growth factor and angiopoietin-2. Here, we report results from two phase I, nonrandomized, dose-escalation studies (NCT02674152 and NCT02689505; funded by Boehringer Ingelheim) evaluating BI 836880 in patients with confirmed locally advanced or metastatic solid tumors, refractory to standard therapy, or for which standard therapy was ineffective. [...]
2022 -  10.1016/j.esmoop.2022.100576
ESMO open, Vol. 7 (september 2022)
|
|
|
2.
|
|
20 p, 620.3 KB |
Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors
/
Moreno, V. (Hospital Universitario Fundación Jiménez Díaz) ;
Greil, R. (IIIrd Medical Department. Paracelsus Medical University. Salzburg Cancer Research Institute) ;
Yachnin, J. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Wermke, M. (Medical Clinic I. University Hospital Carl Gustav Carus. NCT/UCC Early Clinical Trial Unit) ;
Arkenau, Hendrik-Tobias (Cancer Institute. University College London) ;
Basque, J.R. (Novartis Pharma AG) ;
Nidamarthy, P.K. (Novartis Healthcare Private Limited) ;
Kapoor, S. (Novartis Healthcare Private Limited) ;
Cui, X. (Novartis Institutes for BioMedical Research) ;
Giovannini, M. (Novartis Pharmaceuticals Corporation)
Purpose: In the Phase II GEOMETRY mono-1 study, the potent and selective mesenchymal-epithelial transition (MET) inhibitor capmatinib exhibited considerable efficacy in MET exon 14 skipping (METex14)-mutated metastatic non-small cell lung cancer at a dose of 400 mg BID. [...]
2021 - 10.1016/j.clinthera.2021.04.006
Clinical Therapeutics, Vol. 43 Núm. 6 (june 2021) , p. 1092-1111
|
|
|
3.
|
|
12 p, 823.0 KB |
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
/
Hodkinson, Brendan P. (Oncology Translational Research (Estats Units d'Amèrica)) ;
Schaffer, Michael (Oncology Translational Research (Estats Units d'Amèrica)) ;
Brody, Joshua D. (Icahn School of Medicine at Mount Sinai (Estats Units d'Amèrica)) ;
Jurczak, Wojciech (Maria Sklodowska-Curie National Research Institute of Oncology) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Ben-Yehuda, Dina (Hadassah-Hebrew University Medical Center) ;
Avivi, Irit (Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine) ;
Forslund, Ann (Bristol-Myers Squibb) ;
Özcan, Muhit (Ankara University School of Medicine) ;
Alvarez, John (Janssen Research & Development, Spring Housen (Estats Units d'Amèrica)) ;
Ceulemans, Rob (Translational Medicine, Janssen Research & Development) ;
Fourneau, Nele (Translational Medicine, Janssen Research & Development) ;
Younes, Anas (Memorial Sloan Kettering Cancer Center) ;
Balasubramanian, Sriram (Janssen Research & Development (Estats Units d'Amèrica)) ;
Universitat Autònoma de Barcelona
We analyzed potential biomarkers of response to ibrutinib plus nivolumab in biopsies from patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter's transformation (RT) from the LYM1002 phase I/IIa study, using programmed death ligand 1 (PD-L1) immunohistochemistry, whole exome sequencing (WES), and gene expression profiling (GEP). [...]
2020 - 10.1016/j.tranon.2020.100977
Translational Oncology, Vol. 14 (december 2020)
|
|
|
4.
|
|
8 p, 500.4 KB |
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
/
Siena, S. (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ;
Sartore-Bianchi, A. (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ;
García-Carbonero, Rocío (Universidad Complutense de Madrid) ;
Karthaus, M. (Department for Hematology and Oncology, Staedt Klinikum Neuperlach and Harlaching, Munich, Germany) ;
Smith, D. (Bordeaux University Hospital (França)) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Van Cutsem, E. (KU Leuven, Leuven, Belgium) ;
Guan, X (Amgen Inc., Thousand Oaks, CA, USA) ;
Boedigheimer, M. (Amgen Inc., Thousand Oaks, CA, USA) ;
Ang, A. (Amgen Inc., Thousand Oaks, CA, USA) ;
Twomey, B. (Amgen Inc., Thousand Oaks, CA, USA) ;
Bach, B. A. (Amgen Inc., Thousand Oaks, CA, USA) ;
Jung, A. S. (Amgen Inc., Thousand Oaks, CA, USA) ;
Bardelli, Alberto (Department of Oncology, University of Torino, Candiolo, Italy)
Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational status; however, plasma testing of cell-free DNA has been shown to be a more sensitive method for detecting clonal evolution. [...]
2017 - 10.1093/annonc/mdx504
Annals of oncology, Vol. 29 (september 2017) , p. 119-126
|
|
|
5.
|
|
11 p, 542.8 KB |
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
/
Reynolds, Kerry Lynn ;
Bedard, Philippe L (Toronto, ON Canada) ;
Lee, Se-Hoon (Seoul, Republic of Korea) ;
Lin, Chia-Chi (Taipei, Taiwan) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Alsina, Maria (Hospital Universitari Vall d'Hebron) ;
Cohen, Ezra (La Jolla, CA USA) ;
Baselga Torres, Josep, 1959-2021, (New York, NY USA) ;
Blumenschein, George (Houston, TX USA) ;
Graham, Donna M. (Toronto, ON Canada) ;
Garrido-Laguna, Ignacio (Salt Lake City, UT USA) ;
Juric, Dejan (Fruit Street, Boston, MA 02114 USA) ;
Sharma, Sunil (Salt Lake City, UT USA) ;
Salgia, Ravi (Duarte, CA USA) ;
Seroutou, Abdelkader (Basel, Switzerland) ;
Tian, Xianbin (East Hanover, NJ USA) ;
Fernandez, Rose (East Hanover, NJ USA) ;
Morozov, Alex (New York, NY USA) ;
Sheng, Qing (Cambridge, MA USA) ;
Ramkumar, Thiruvamoor (East Hanover, NJ USA) ;
Zubel, Angela (Basel, Switzerland) ;
Bang, Yung-Jue (Seoul, Republic of Korea) ;
Universitat Autònoma de Barcelona
Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal growth factor receptor-driven cancers and mediating resistance to targeted therapy. A phase I study of anti-HER3 monoclonal antibody LJM716 was conducted with the primary objective to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE), and dosing schedule. [...]
2017 - 10.1186/s12885-017-3641-6
BMC Cancer, Vol. 17 (september 2017)
|
|
|
6.
|
|
11 p, 1018.7 KB |
Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
/
Hancock, Gemma ;
Moron-Lopez, Sara (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Kopycinski, Jakub ;
Puertas, Maria C.. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Giannoulatou, Eleni (University of New South Wales) ;
Rose, Annie ;
Salgado, Maria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Hayton, Emma-Jo ;
Crook, Alison ;
Morgan, Catharine ;
Angus, Brian ;
Chen, Fabian ;
Yang, Hongbing ;
Martinez-Picado, Javier (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Hanke, Tomáš ;
Dorrell, Lucy ;
Universitat Autònoma de Barcelona
Introduction : Vaccines may be key components of a curative strategy for HIV-1. We investigated whether a novel immunogen, HIVconsv, designed to re-direct T cell responses to conserved viral epitopes, could impact the HIV-1 reservoir in chronic antiretroviral therapy (ART)-treated subjects when delivered by modified vaccinia virus Ankara (MVA). [...]
2017 - 10.7448/IAS.20.1.21171
Journal of the International AIDS Society, Vol. 20 (may 2017)
|
|
|
7.
|
|
13 p, 501.3 KB |
A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function
/
Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Rodón, Jordi (Hospital Universitari Vall d'Hebron) ;
Machiels, Jean-Pascal (Institut Roi Albert II (Bèlgica). Department of Medical Oncology) ;
Rottey, Sylvie (Universitair Ziekenhuis Gent) ;
Damian, Silvia (National Cancer Institute of Milan) ;
Baird, Richard (Early Phase Clinical Trials Team, Department of Oncology, University of Cambridge, Cambridge, UK) ;
Garcia-Corbacho, Javier (Early Phase Clinical Trials Team, Department of Oncology, University of Cambridge, Cambridge, UK) ;
Mathijssen, Ron H. J. (Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands) ;
Clot, Pierre-François (Sanofi, Chilly-Mazarin, France) ;
Wack, Claudine (Sanofi, Chilly-Mazarin, France) ;
Shen, Liji (Sanofi, Bridgewater, NJ USA) ;
de Jonge, Maja (Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands)
Limited data are available on cabazitaxel pharmacokinetics in patients with renal impairment. This open-label, multicenter study assessed cabazitaxel in patients with advanced solid tumors and normal or impaired renal function. [...]
2016 - 10.1007/s00280-016-3175-7
Cancer Chemotherapy and Pharmacology, Vol. 78 (october 2016) , p. 1185-1197
|
|
|
8.
|
|
10 p, 426.6 KB |
A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies
/
Spreafico, A. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ;
Delord, Jean-Pierre (Institut Claudius Regaud (France)) ;
Mattos Arruda, Leticia de (Hospital Universitari Vall d'Hebron) ;
Berge, Y. (Institut Claudius Regaud (France)) ;
Pérez Rodon, Jordi (Hospital Universitari Vall d'Hebron) ;
Cottura, E. (Institut Claudius Regaud (France)) ;
Bedard, Philippe L (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ;
Akimov, Mikhail (Novartis Pharma AG (Switzerland)) ;
Lu, H. (Novartis Pharmaceuticals Corp (USA)) ;
Pain, S. (Novartis Pharmaceuticals Corp (USA)) ;
Kaag, A. (Novartis Pharma AG (Switzerland)) ;
Siu, L. L. (University of Toronto. Princess Margaret Cancer Centre. Division of Medical Oncology and Hematology (Canada)) ;
Cortés, Javier (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Heat-shock protein 990 (HSP990) is a potent and selective synthetic small-molecule HSP90 inhibitor. The primary objectives of this phase I first-in-human study were to determine dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD) and recommended phase II dose (RP2D). [...]
2015 - 10.1038/bjc.2014.653
British Journal of Cancer, Vol. 112 (February 2015) , p. 650-659
|
|
|
9.
|
|
8 p, 455.0 KB |
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer : a phase I/II randomized trial
/
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Keedy, Vicki (Vanderbilt University Medical Center) ;
Borghaei, Hossein (Fox Chase Cancer Center, Philadelphia) ;
Shepherd, Frances A. (University of Toronto) ;
Insa, Amelia (Hospital Clínic Universitari (València)) ;
Brown, Holly (Merck & Co., Inc., Whitehouse Station) ;
Fitzgerald, Timothy (Merck & Co., Inc., Whitehouse Station) ;
Sathyanarayanan, Sriram (Whitehouse Station, NJ USA) ;
Reilly, John F.. (Merck & Co., Inc., Whitehouse Station) ;
Mauro, David (Merck & Co., Inc., Whitehouse Station) ;
Hsu, Karl (Sanofi Aventis) ;
Yan, Li (Merck & Co., Inc., Whitehouse Station) ;
Universitat Autònoma de Barcelona
We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselected patients with refractory advanced non-small-cell lung cancer (NSCLC). [...]
2014 - 10.1186/2162-3619-3-26
Experimental Hematology & Oncology, Vol. 3 (november 2014)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
